Clearstead Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Clearstead Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$21	Buy	+3	New	+$28	﹤0.01%	3423

Other funds holding CRBP

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Clearstead Advisors's CRBP Position: Q3 2026 in Review

Clearstead Advisors opened a new position in Corbus Pharmaceuticals (CRBP) in Q3 2026: 3 shares worth $21. The stake represents ﹤0.01% of the portfolio and ranks #3423 among its holdings.

44 funds tracked by Wall St. Rank hold CRBP as of Q3 2026.

Clearstead Advisors held 3 shares of Corbus Pharmaceuticals worth $21 as of Q3 2026.
Corbus Pharmaceuticals was a new Clearstead Advisors position in Q3 2026.
Corbus Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q3 2026, its #3423 holding.
44 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2026.

Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.